secwatch.observer — SEC 8-K summary
======================================

Issuer:     Eledon Pharmaceuticals, Inc. (ELDN)
CIK:        0001404281
Form:       8-K
Filed at:   2024-03-28T23:59:59+00:00
Accession:  0000950170-24-038008
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Eledon posts Q4 net loss $9.6M, highlights Phase 2 BESTOW enrollment and xenotransplant use
--------------------------------------------------------------------------------

- Net loss of $9.6M ($0.32/shr) for Q4 2023; full year net loss $40.3M ($1.64/shr).
- Cash and equivalents $51.1M as of Dec 31, 2023; down from $56.4M year-end 2022.
- 12 participants enrolled in Phase 2 BESTOW trial of tegoprubart vs tacrolimus in kidney transplant.
- Phase 1b data (n=11) showed tegoprubart safe, with eGFR >70 mL/min at all post-90-day time points.
- Tegoprubart used in first pig-to-human kidney xenotransplant on March 16, 2024 at Massachusetts General Hospital.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1404281/000095017024038008/0000950170-24-038008-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1404281/000095017024038008/eldn-20240328.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-038008

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer